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Abstract
Background Early (B24 h) systemic procalcitonin (PCT)
levels are predictive for unfavorable neurological outcome
in patients after out-of-hospital cardiac arrest (OHCA).
Subarachnoid hemorrhage (SAH) due to aneurysm rupture
might lead to a cerebral perfusion stop similar to OHCA.
The current study analyzed the association of early PCT
levels and outcome in patients after SAH.
Methods Data from 109 consecutive patients, admitted
within 24 h after SAH, were analyzed. PCT levels were
measured within 24 h after ictus. Clinical severity was
determined using the World Federation of Neurological
Societies (WFNS) scale and dichotomized into severe
(grade 4–5) and non-severe (1–3). Neurological outcome
after 3 months was assessed by the Glasgow outcome scale
and dichotomized into unfavorable (1–3) and favorable
(4–5). The predictive value was assessed using receiver
operating curve (ROC) analysis.
Results Systemic PCT levels were significantly higher in
patients with severe SAH compared to those with non-
severe SAH: 0.06 ± 0.04 versus 0.11 ± 0.11 lg/l
(median ± interquartile range; p < 0.01). Patients with
unfavorable outcome had significantly higher PCT levels
compared to those with favorable outcome 0.09 ± 0.13
versus 0.07 ± 0.15 ng/ml (p < 0.01). ROC analysis
showed an area under the curve of 0.66 (p < 0.01) for
PCT, which was significantly lower than that of WFNS
with 0.83 (p < 0.01).
Conclusions Early PCT levels in patients with SAH
might reflect the severity of the overall initial stress
response. However, the predictive value is poor, especially
compared to the reported predictive values in patients with
OHCA. Early PCT levels might be of little use in pre-
dicting neurological outcome after SAH.
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Introduction
Current evidence suggests that treatment of cerebral
vasospasm (CVS) alone does not avoid the occurrence of
neuronal injury, i.e., delayed cerebral ischemia (DCI), with
consequent poor outcome in patients with aneurysmal
subarachnoid hemorrhage (aSAH) [1, 2]. More recently,
mechanisms of early brain injury have moved center stage
in the research focus. It has been suggested that these
mechanisms evolve with time and contribute to the path-
ogenesis of DCI [3, 4]. The rupture of an aneurysm and
consequent release of blood into the subarachnoid space
leads to an abrupt increase of the intracranial pressure
(ICP), which is suggested to cause a brief cerebral perfu-
sion arrest [4].
Out-of-hospital cardiac arrest (OHCA) is associated
with brief cerebral perfusion stop as well. More recently,
early elevated systemic procalcitonin (PCT) levels have
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been described to accurately predict unfavorable neuro-
logical outcome after OHCA [5–7]. Increased PCT levels
have been sparsely described with regard to the course of
illness after aSAH [8, 9]. However, the prognostic value of
early PCT levels in patients with aSAH is unknown. The
current study intended to evaluate the prognostic value of
early PCT levels on the neurological outcome after aSAH.
Materials and Methods
The database consisted of prospectively collected data of
231 patients with confirmed aSAH, admitted at the Neur-
ocritical Care Unit, University Hospital Zurich (an
academic tertiary care center), during a 3-year period, from
2007 to 2009. In brief, the diagnosis was based on either
CT or catheter angiography. The clinical severity at time of
admission was assessed according to the World Federation
of Neurological Surgeons (WFNS) grading [10]. The
radiological severity was assessed based on the Fisher
grading [11]. All patients were treated according to a
standardized treatment protocol as previously described
[12, 13]. Neurological outcome was assessed 3 months
after aSAH in the outpatient clinic according to the Glas-
gow outcome scale (GOS). For the current study only
patients with admission and PCT level measured within
24 h after ictus were included. Patients with rebleeding
after admission were also excluded. The study was
approved by the local ethics committee.
PCT measurements were performed by the Institute of
Clinical Chemistry, University Hospital Zurich, using an
electrochemiluminescence immunoassay. Blood sampling
and measurements were performed in terms of clinical
routine, i.e., no additional blood sampling was performed.
Having a potential influence on the PCT levels, we asses-
sed the presence of a systemic inflammatory response
syndrome (SIRS) and pneumonia at time of admission [14].
As the assessment and interpretation of classic SIRS
symptoms was hampered in the current study population
[15, 16], the presence of SIRS was assumed when C2 of
the following conditions were present: Body tempera-
ture >38.5 C, leukocyte count <4,000/ll or >12,000/
ll, and volume-resistant shock syndrome with the need of
epinephrine >30 lg/min. Pneumonia was assumed to be
present if specific signs of alveolar infiltrate on chest X-ray
and microorganisms from tracheobronchial secretion cul-
tures were present.
Categorical variables were described using frequency
and percentage. Patients’ ages were given as
mean ± standard deviation (SD). PCT levels were given as
median ± interquartile range (IQR) due to its variance. For
statistical analysis, WFNS grade was dichotomized into
clinically severe (WFNS 4–5) and non-severe (WFNS 1–3)
and GOS in unfavorable (GOS 1–3) and favorable (GOS
4–5). Binominal variables were compared between the
groups by the Fisher’s exact test, and continuous variables
by the independent t test. PCT values were compared using
the Mann–Whitney U or Kruskal–Wallis test, as normal
distribution was not present. Receiver operating charac-
teristics (ROC) analysis was performed to assess and
compare the predictive value of early PCT values with
known predictors. Sensitivity and specificity were calcu-
lated using the cut-off value of 0.50 ng/ml for PCT, which
has been described as optimal in patients with OHCA [5,
6]. A p value <0.05 was regarded as statistically signifi-
cant. IBM SPSS Statistics 20.0 Software was used.
Results
Out of 231 patients, a total of 109 (47 %) fulfilled the
inclusion criteria. The patients’ characteristics are sum-
marized in Table 1. Unfavorable neurological outcome
after 3 months was observed in 32 patients (29 %). Two of
them underwent cardio-pulmonary resuscitation prior to
admission. As expected, patients with unfavorable outcome
presented with clinically and radiologically severe aSAH
(both p < 0.01) and tended to be more elderly (p = 0.05).
The presence of SIRS was higher in patients with unfa-
vorable outcome, however, without any statistical
significance. Ruptured aneurysm location and the assumed
presence of pneumonia at time of admission were statisti-
cally not different. The results are summarized in Table 1.
Systemic PCT levels were significantly higher in patients
with severe than in patients with non-severe aSAH:
0.06 ± 0.04 versus 0.11 ± 0.11 lg/l (p < 0.01) (Fig. 1a).
Patients with radiologically severe aSAH also had higher
PCT levels; however, there was no statistical significance
between patients presenting with Fisher 1–2 and 3
(Fig. 1b). Furthermore, systemic PCT levels within 24 h
after ictus were significantly higher in patients with unfa-
vorable compared to patients with favorable outcome:
0.09 ± 0.13 versus 0.07 ± 0.15 ng/ml (p < 0.01)
(Fig. 1c). Two patients underwent cardio-pulmonary
resuscitation prior to admission. Both of them also had a
clinically and radiologically severe bleeding. PCT levels at
admission were 0.29 and 0.68 ng/ml, respectively. Both
patients survived. However, functional outcome was
unfavorable.
The ROC curve analysis showed an area under the curve
(AUC) of 0.66 (p < 0.01; 95 % CI: 0.55–0.77) for PCT,
0.64 (p = 0.02; 95 % CI: 0.53–0.75) for age, 0.83
(p < 0.01; 95 % CI: 0.74–0.91) for WFNS, and 0.68
(p < 0.05; 95 % CI: 0.57–0.79) for Fisher grade (Fig. 2).
Analysis of the combined predictive probability (age,
WFNS, and Fisher grade) with and without PCT revealed
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an AUC of 0.88 (p < 0.01; 95 % CI: 0.81–0.91) and 0.87
(p < 0.01; 95 % CI: 0.80–0.94), respectively (Fig. 2).
Using the PCT cut-off value of 0.50 ng/ml, the sensitivity
was poor (12 %), while the specificity was high (94 %).
The ROC curves are shown in Fig. 2.
Discussion
In the current study we intended to assess the predictive
value of early PCT values (B24 h after ictus) with regard
to the neurological outcome after aSAH. The results
showed increased PCT levels in patients with initially
severe hemorrhage and in patients with clinically unfa-
vorable outcome. Based on the ROC curve analysis, the
predictive value of PCT on the neurological outcome was
poor to moderate and by that showed to be far less pre-
dictive than WFNS grade. Comparing the combined
predictive probabilities of well-known risk factors (WFNS,
Fisher grade, and age) with and without PCT, the inclusion
of PCT showed virtually no advantage.
Little is known about the origin, liberation kinetics, or
pathophysiology of PCT. The acute-phase protein has been
reported to be a useful biomarker to determine bacterial
infection or sepsis [14]. In particular, it has been reported
to allow discrimination between sepsis and SIRS. How-
ever, more recent evidence suggests that PCT can also be
elevated under various other ‘‘acute stress conditions,’’
such as polytrauma, heat stroke, cardiac arrest, burns,
traumatic brain injury, and aSAH [8, 9, 14, 17]. Post-car-
diac-arrest status has been designated as a ‘‘sepsis-like’’
syndrome [18, 19]. Moreover, transient myocardial dys-
function can occur after resuscitation, mainly as a result of
‘‘myocardial stunning’’ [19], which might further aggravate
ischemic–hypoxic brain injury. It is of particular interest
that high specificity and sensitivity of early PCT values in
Table 1 Patients characteristics
GOS Glasgow outcome scale,
Sig significance, SIRS systemic
inflammatory response
syndrome, WFNS world
federation of neurological
surgeons
All patients (n = 109) GOS 1–3 (n = 32) GOS 4–5 (n = 77) Sig.
Sex
Female 67 (62 %) 23 (72 %) 44 (57 %) p = 0.196
Male 42 (38 %) 9 (28 %) 33 (43 %)
Age 54.0 ± 13.8 58 ± 13.8 52.3 ± 13.5 p = 0.050
WFNS Grade
1–3 65 (60 %) 7 (22 %) 58 (75 %) p < 0.001
4–5 44 (40 %) 25 (76 %) 19 (25 %)
Aneurysm location
Anterior circulation 82 (75 %) 24 (75 %) 58 (75 %) p > 0.999
Posterior circulation 27 (25 %) 8 (25 %) 24 (25 %)
SIRS 7 (6 %) 4 (13 %) 3 (4 %) p = 0.191
Pneumonia 4 (4 %) 2 (6 %) 2 (3 %) p = 0.579
Fig. 1 PCT levels (B24 h) shown as box-plots. a Patients with
clinically severe aSAH (WFNS 4–5) had significantly higher PCT
levels. b Patients with radiologically severe aSAH had significantly
higher PCT levels. There was no statistical significance between
patients presenting with Fisher grade 1–2 and 3. c Patients with
unfavorable outcome (GOS 1–3) had significantly higher PCT levels
compared to patients with favorable outcome (GOS 4–5). PCT levels
are logarithmically transformed for illustrative purposes
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predicting neurological outcome have been reported [5–7,
20]. In particular, PCT levels >0.50 ng/ml at day one after
OHCA showed a sensitivity of 91.7 % and specificity of
100 % in one study [5]. In another study a sensitivity of
100 % and specificity of 81.3 % was reported [6]. ROC
curve analysis of the two studies revealed an AUC of 0.98
and 0.94, respectively [5, 6].
The rupture of an intracranial aneurysm is associated
with a sudden ICP increase and may reach values as high as
162 mmHg [3, 21, 22]. The sharp increase of ICP leads to a
decrease of the cerebral perfusion pressure (CPP) with a
consequent critical decrease of the cerebral blood flow
(CBF) [22–24]. In severe hemorrhage, intracranial circu-
latory arrest lasting for several minutes might occur [22,
25], which might be comparable with intracranial circula-
tory arrest after OHCA. Furthermore, a ‘‘neurogenic
stunned myocardium’’ with consecutive cardiac dysfunc-
tion might occur, with similar effects as the ‘‘myocardial
stunning’’ after OHCA [26]. However, with only 2 patients,
the number of patients with documented cardio-pulmonary
resuscitation in the current study population was low. The
current results show increased PCT levels in patients with
clinically and radiologically severe aSAH. It can be
assumed that these patients suffered more seriously from
cerebral circulatory compromise at the time of hemorrhage.
The PCT levels probably reflect an acute systemic stress
response to the hemorrhage. Although patients with unfa-
vorable outcome showed significantly higher PCT levels
within 24 h after ictus, the predictive value for unfavorable
neurological outcome was rather poor compared to previ-
ous reports on patients after OHCA. This might be
explained as follows: Early brain injury after aSAH cannot
be (over-) simplified to transient global cerebral hypoxia
due to CBF decrease or arrest. There are several patho-
physiological mechanisms that activate within minutes
after the initial bleeding such as mechanical and bio-
chemical trauma caused by the hematoma itself [3].
Furthermore, it is well known that patients with aSAH are
specifically at risk of secondary neurological injury, which
may be caused by 1) CVS-dependent or -independent
delayed ischemic events, aka DCI, 2) ‘‘collateral damage’’
in conjunction with the aneurysm securement, and/or 3)
rebleeding [1, 27].
With respect to the current results, following limitations
have to be considered. The crucial disadvantage of the
current study is its anecdotal nature. Furthermore, the
database was derived from a single tertiary care center and,
therefore, might carry the risk of being biased as well as of
over representing severe cases.
Conclusion
Early elevated systemic PCT levels in patients with severe
aSAH might reflect the overall initial stress response. In the
current study, patients with unfavorable neurological out-
come had higher PCT levels within 24 h after ictus.
However, their predictive value appeared to be poor,
especially compared to the reported predictive values in
patients with OHCA. Therefore, early PCT levels might be
of little practical use in predicting neurological outcome
after aSAH. Furthermore, the results underline once more
the pathophysiological complexity of neuronal injury after
aSAH.
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